GlassScriptPhysician profile
Robin D'Anne Thompson
NPI 1942263892
$4,462.80
in general payments reported to CMS, 2019-2025
21 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $11.59 · 2021: $20.34 · 2022: $375 · 2023: $1,156 · 2024: $1,089 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,439.11 |
| Education | $379.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,035.72 | 2022-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $563.90 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $412.01 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $392.51 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $276.02 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $273.18 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $256.97 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $240.34 | 2023-2024 | |
| Amgen INC. | $225.89 | 2023-2025 | Otezla, Otezla |
| Pfizer INC. | $157.68 | 2019-2025 | |
| Galderma Laboratories, L.P. | $154.51 | 2023-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $112.97 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $73.98 | 2023 | Vtama |
| Incyte Corporation | $73.35 | 2021-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $66.31 | 2019-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $57.85 | 2024-2025 | Zoryve |
| Journey Medical Corporation | $23.64 | 2023 | |
| Lnhc, INC | $17.37 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.39 | 2022 | |
| Biofrontera INC. | $16.29 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $15.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.